{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:20:55Z","timestamp":1786990855418,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ijtb.2021.06.003","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T03:04:43Z","timestamp":1624676683000},"page":"354-358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ruxolitinib and tuberculosis: A case report with brief review"],"prefix":"10.1016","volume":"69","author":[{"given":"Neema","family":"Tiwari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparajita","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6911-9064","authenticated-orcid":false,"given":"Shailendra Prasad","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil Kumar","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijtb.2021.06.003_bib1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajh.24221","article-title":"Myeloproliferative neoplasms: a decade of discoveries and treatment advances","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ijtb.2021.06.003_bib2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2008.72","article-title":"Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders","volume":"22","author":"Cervantes","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ijtb.2021.06.003_bib3","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ijtb.2021.06.003_bib4","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","article-title":"Diagnosis, risk stratification, and response evaluation in classical MPN","volume":"129","author":"Rumi","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ijtb.2021.06.003_bib5","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3904\/kjim.2018.033","article-title":"Recent advances in the diagnosis and management of primary myelofibrosis","volume":"33","author":"Takenaka","year":"2018","journal-title":"Korean J Intern Med"},{"issue":"11","key":"10.1016\/j.ijtb.2021.06.003_bib6","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-14-3198","article-title":"JAK inhibition impairs NK cell function in myeloproliferative neoplasms","volume":"75","author":"Sch\u00f6nberg","year":"2015","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ijtb.2021.06.003_bib7","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.13373","article-title":"JAK1\/2 inhibition impairs T cell function in\u00a0vitro and in patients with myeloproliferative neoplasms","volume":"169","author":"Parampalli Yajnanarayana","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijtb.2021.06.003_bib8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: a systematic review and metaanalysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.ijtb.2021.06.003_bib9","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","article-title":"Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Mesa","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijtb.2021.06.003_bib10","first-page":"2389038","article-title":"Reactivation of pulmonary tuberculosis following treatment of myelofibrosis with ruxolitinib","volume":"2016","author":"Abidi","year":"2016","journal-title":"Case Rep Hematol"},{"issue":"7","key":"10.1016\/j.ijtb.2021.06.003_bib11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00277-016-2684-0","article-title":"Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib","volume":"95","author":"Branco","year":"2016","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.ijtb.2021.06.003_bib12","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3109\/10428194.2014.963082","article-title":"Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis","volume":"56","author":"Chen","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijtb.2021.06.003_bib13","doi-asserted-by":"crossref","DOI":"10.1186\/1756-0500-5-552","article-title":"Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report","volume":"5","author":"Colomba","year":"2012","journal-title":"BMC Res Notes"},{"issue":"8","key":"10.1016\/j.ijtb.2021.06.003_bib14","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/leu.2014.104","article-title":"Disseminated tuberculosis associated with ruxolitinib","volume":"28","author":"Hopman","year":"2014","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.ijtb.2021.06.003_bib15","article-title":"Fatal tuberculosis during treatment with ruxolitinib","volume":"159","author":"Keizer","year":"2015","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.ijtb.2021.06.003_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1155\/2015\/284168","article-title":"Ruxolitinib associated tuberculosis presenting as a neck lump","volume":"2015","author":"shamil","year":"2015","journal-title":"Case Reports in Infectious Diseases"},{"key":"10.1016\/j.ijtb.2021.06.003_bib17","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3855\/jidc.9993","article-title":"Tuberculosis reactivation related with ruxolitinib in patients with primary myelofibrosis","volume":"12","author":"Pepeler","year":"2018","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.ijtb.2021.06.003_bib18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijid.2019.01.002","article-title":"Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera","volume":"80","author":"Lescuyer","year":"2019","journal-title":"Int J Infect Dis"},{"issue":"11","key":"10.1016\/j.ijtb.2021.06.003_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a017830","article-title":"Diagnosis and management of latent tuberculosis infection","volume":"5","author":"Mu\u00f1oz","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"10.1016\/j.ijtb.2021.06.003_bib20","first-page":"775","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis [published correction appears in Leukemia","volume":"31","author":"Harrison","year":"2017"},{"issue":"7","key":"10.1016\/j.ijtb.2021.06.003_bib21","first-page":"4195","article-title":"Tuberculosis: Latency and reactivation","volume":"69","author":"JoAnne","year":"2001","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.ijtb.2021.06.003_bib22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4103\/lungindia.lungindia_181_19","article-title":"Prevalence of pulmonary tuberculosis in India: a systematic review and meta-analysis","volume":"37","author":"Sathiyamoorthy","year":"2020","journal-title":"Lung India"},{"issue":"10","key":"10.1016\/j.ijtb.2021.06.003_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01582-19","article-title":"Advances in molecular\u00a0diagnosis of tuberculosis","volume":"58","author":"MacLean","year":"2020","journal-title":"J Clin Microbiol"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570721001086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570721001086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T04:00:24Z","timestamp":1758081624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570721001086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0019570721001086"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2021.06.003","relation":{},"ISSN":["0019-5707"],"issn-type":[{"value":"0019-5707","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ruxolitinib and tuberculosis: A case report with brief review","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2021.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}